Shanghai LaiShi: SR604 injection adds new clinical trial indication application received accepted.

Shanghai Raas announcement, recently received the "Acceptance Notice" issued by the National Medical Products Administration, agreeing to accept the company's application for conducting clinical trials on the indication of "prevention and treatment of bleeding episodes in patients with vascular hemophilia" for the SR604 injection. SR604 injection is a humanized high-affinity monoclonal antibody preparation combining human activated protein C. It has previously been accepted and entered the efficacy exploration Phase IIb trial stage. If the indication being applied for this time is successfully developed, it is expected to significantly improve the medication experience of patients with vascular hemophilia. There are currently no products on the market with the same target as this drug globally, and no antibody drugs approved for marketing for the prevention and treatment of vascular hemophilia.